Broccoli sprout extract for memory and thinking in mild cognitive impairment
Tests broccoli sprout extract for thinking skills and safety in adults with mild cognitive impairment.
Key facts
- Who runs it
- Pusan National University Yangsan Hospital
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Broccoli Sprout Extract for Cognitive Function
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 16 Apr 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Broccoli sprout extract (BSE)
- Placebo Control
- Record updated
- 13 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with mild memory or thinking problems but no dementia. Participants take broccoli sprout extract or a placebo for 12 weeks.
- Age
- 55 to 85 years in the criteria (the registry age fields say 50 to 85 years).
- Sex
- Men and women can join.
- Disease stage
- Global Deterioration Scale (GDS) score of 2-3: memory complaints without test evidence (GDS 2), or mild memory problems shown on tests (GDS 3). No dementia.
- Earlier treatment
- No drugs or health functional foods that may affect thinking in the past month, such as antipsychotics, cognitive enhancers, tricyclic antidepressants or hormone replacement therapy. No other drug trial in the past month.
Main reasons for not taking part
- Dementia, Parkinson's disease, stroke or other conditions linked to memory decline.
- Serious stroke, heart disease or cancer in the past 6 months.
- Uncontrolled blood pressure (≥160/100 mmHg) or, in people with diabetes, fasting blood sugar ≥160 mg/dL (8.9 mmol/L).
- Kidney or liver problems (creatinine, AST or ALT ≥2 times the upper limit of normal), or uncontrolled thyroid disease.
- Severe alcohol use disorder, severe stomach symptoms, allergy to the study product, or not able to read Korean.
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age: Adults aged 55-85 years (inclusive), both male and female
- Global Deterioration Scale (GDS) score of 2-3:; GDS 2: Subjective memory impairment without objective evidence GDS 3: Mild objective memory impairment
- Absence of dementia according to established diagnostic criteria
- Ability to read Korean
Who cannot take part
- Uncontrolled thyroid dysfunction: Currently receiving treatment for uncontrolled hypothyroidism or hyperthyroidism
- Other clinical trial participation: Participation in other drug clinical trials within the past month or planned participation during the study period
- Severe medical conditions within the past 6 months: History of severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage), cardiac disease (angina, myocardial infarction, heart failure, arrhythmia requiring treatment), or malignancy (Note: Participants with a history of cerebrovascular or cardiac disease who are clinically stable may be included at the investigator's discretion)
- Cognitive impairment-associated diseases: Dementia, Parkinson's disease, cerebral infarction, or other conditions associated with cognitive decline Uncontrolled hypertension: Blood pressure ≥160/100 mmHg (measured after 10 minutes of rest)
- Medications affecting cognitive function within the past month: Use of drugs (antipsychotics, anti-degenerative agents, cognitive enhancers, tricyclic antidepressants, hormone replacement therapy) or health functional foods that may influence cognitive function due to dementia or other cognitive abnormalities
- Alcohol use disorder, severe
- Food allergies: Known allergic reactions to study product components
- Investigator discretion: Any other condition deemed inappropriate for study participation by the investigator
- Poor glycemic control: Fasting blood glucose ≥160 mg/dL in diabetic patients
- Renal impairment: Serum creatinine ≥2 times the upper limit of normal for the institution
- Hepatic impairment: AST or ALT ≥2 times the upper limit of normal for the institution
- Severe gastrointestinal symptoms: Complaints of severe heartburn, dyspepsia, or other gastrointestinal distress
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
This trial is currently available in South Korea.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial aims to determine whether broccoli sprout extract improves cognitive function in adults with mild cognitive impairment and to assess its safety.
Read full original descriptionShow less
The main questions are:
* Does broccoli sprout extract improve cognitive function in participants? * What side effects occur when participants take broccoli sprout extract?
The 2 groups in the trial
- Broccoli groupTreatment being tested
This group takes broccoli sporout extract for 12 weeks.
Treatment: Broccoli sprout extract (BSE)
- Placebo groupPlacebo, for comparison
This group takes placebo for 12 weeks.
Treatment: Placebo Control
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A 12-week Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Broccoli Sprout Extract on Cognitive Function Improvement in Adults With Mild Cognitive Impairment
- Plain-language title
- Broccoli sprout extract for memory and thinking in mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07334366, who can take part
- Record updated
- 13 January 2026